nodes	percent_of_prediction	percent_of_DWPC	metapath
Tobramycin—Productive cough—Telbivudine—hepatitis B	0.0591	0.0591	CcSEcCtD
Tobramycin—Nephrotoxicity—Adefovir Dipivoxil—hepatitis B	0.0443	0.0443	CcSEcCtD
Tobramycin—Musculoskeletal chest pain—Telbivudine—hepatitis B	0.0306	0.0306	CcSEcCtD
Tobramycin—Nephropathy toxic—Adefovir Dipivoxil—hepatitis B	0.0245	0.0245	CcSEcCtD
Tobramycin—Platelet count decreased—Entecavir—hepatitis B	0.0243	0.0243	CcSEcCtD
Tobramycin—Hypophosphataemia—Adefovir Dipivoxil—hepatitis B	0.0242	0.0242	CcSEcCtD
Tobramycin—Transaminases increased—Entecavir—hepatitis B	0.0237	0.0237	CcSEcCtD
Tobramycin—Serum creatinine increased—Entecavir—hepatitis B	0.0235	0.0235	CcSEcCtD
Tobramycin—Serum creatinine increased—Adefovir Dipivoxil—hepatitis B	0.0229	0.0229	CcSEcCtD
Tobramycin—Pharyngolaryngeal pain—Telbivudine—hepatitis B	0.0176	0.0176	CcSEcCtD
Tobramycin—Laryngeal pain—Telbivudine—hepatitis B	0.0174	0.0174	CcSEcCtD
Tobramycin—Cough increased—Adefovir Dipivoxil—hepatitis B	0.0154	0.0154	CcSEcCtD
Tobramycin—Creatinine increased—Adefovir Dipivoxil—hepatitis B	0.0148	0.0148	CcSEcCtD
Tobramycin—Chest discomfort—Telbivudine—hepatitis B	0.0134	0.0134	CcSEcCtD
Tobramycin—Renal impairment—Adefovir Dipivoxil—hepatitis B	0.0107	0.0107	CcSEcCtD
Tobramycin—Blood creatinine increased—Entecavir—hepatitis B	0.00982	0.00982	CcSEcCtD
Tobramycin—Blood creatinine increased—Adefovir Dipivoxil—hepatitis B	0.00958	0.00958	CcSEcCtD
Tobramycin—Renal impairment—Telbivudine—hepatitis B	0.00905	0.00905	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Entecavir—hepatitis B	0.00842	0.00842	CcSEcCtD
Tobramycin—Dysphonia—Lamivudine—hepatitis B	0.00812	0.00812	CcSEcCtD
Tobramycin—Weight decreased—Adefovir Dipivoxil—hepatitis B	0.008	0.008	CcSEcCtD
Tobramycin—Renal failure—Entecavir—hepatitis B	0.00794	0.00794	CcSEcCtD
Tobramycin—Aspartate aminotransferase increased—Telbivudine—hepatitis B	0.00775	0.00775	CcSEcCtD
Tobramycin—Renal failure—Adefovir Dipivoxil—hepatitis B	0.00775	0.00775	CcSEcCtD
Tobramycin—Muscular weakness—Telbivudine—hepatitis B	0.00759	0.00759	CcSEcCtD
Tobramycin—Bone disorder—Lamivudine—hepatitis B	0.0074	0.0074	CcSEcCtD
Tobramycin—Sinusitis—Adefovir Dipivoxil—hepatitis B	0.00739	0.00739	CcSEcCtD
Tobramycin—Oropharyngeal pain—Lamivudine—hepatitis B	0.00735	0.00735	CcSEcCtD
Tobramycin—Drug interaction—Lamivudine—hepatitis B	0.00721	0.00721	CcSEcCtD
Tobramycin—Hearing impaired—Lamivudine—hepatitis B	0.00702	0.00702	CcSEcCtD
Tobramycin—Pharyngitis—Adefovir Dipivoxil—hepatitis B	0.00702	0.00702	CcSEcCtD
Tobramycin—Urinary tract disorder—Adefovir Dipivoxil—hepatitis B	0.00699	0.00699	CcSEcCtD
Tobramycin—Connective tissue disorder—Adefovir Dipivoxil—hepatitis B	0.00695	0.00695	CcSEcCtD
Tobramycin—Urethral disorder—Adefovir Dipivoxil—hepatitis B	0.00693	0.00693	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Telbivudine—hepatitis B	0.00692	0.00692	CcSEcCtD
Tobramycin—Immune system disorder—Entecavir—hepatitis B	0.00655	0.00655	CcSEcCtD
Tobramycin—Renal failure—Telbivudine—hepatitis B	0.00652	0.00652	CcSEcCtD
Tobramycin—Neuropathy peripheral—Telbivudine—hepatitis B	0.0065	0.0065	CcSEcCtD
Tobramycin—Wheezing—Lamivudine—hepatitis B	0.00649	0.00649	CcSEcCtD
Tobramycin—Back pain—Adefovir Dipivoxil—hepatitis B	0.00596	0.00596	CcSEcCtD
Tobramycin—Pharyngitis—Telbivudine—hepatitis B	0.00591	0.00591	CcSEcCtD
Tobramycin—Connective tissue disorder—Telbivudine—hepatitis B	0.00585	0.00585	CcSEcCtD
Tobramycin—Anaemia—Adefovir Dipivoxil—hepatitis B	0.00569	0.00569	CcSEcCtD
Tobramycin—Leukopenia—Entecavir—hepatitis B	0.00565	0.00565	CcSEcCtD
Tobramycin—Deafness—Lamivudine—hepatitis B	0.00542	0.00542	CcSEcCtD
Tobramycin—Cough—Adefovir Dipivoxil—hepatitis B	0.00537	0.00537	CcSEcCtD
Tobramycin—Mediastinal disorder—Telbivudine—hepatitis B	0.00537	0.00537	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Entecavir—hepatitis B	0.00534	0.00534	CcSEcCtD
Tobramycin—Chest pain—Adefovir Dipivoxil—hepatitis B	0.00524	0.00524	CcSEcCtD
Tobramycin—Myalgia—Adefovir Dipivoxil—hepatitis B	0.00524	0.00524	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Adefovir Dipivoxil—hepatitis B	0.00521	0.00521	CcSEcCtD
Tobramycin—Anaphylactic shock—Entecavir—hepatitis B	0.00515	0.00515	CcSEcCtD
Tobramycin—Renal impairment—Lamivudine—hepatitis B	0.0051	0.0051	CcSEcCtD
Tobramycin—Dysgeusia—Telbivudine—hepatitis B	0.00508	0.00508	CcSEcCtD
Tobramycin—Nervous system disorder—Entecavir—hepatitis B	0.00505	0.00505	CcSEcCtD
Tobramycin—Back pain—Telbivudine—hepatitis B	0.00502	0.00502	CcSEcCtD
Tobramycin—Skin disorder—Entecavir—hepatitis B	0.005	0.005	CcSEcCtD
Tobramycin—Nervous system disorder—Adefovir Dipivoxil—hepatitis B	0.00493	0.00493	CcSEcCtD
Tobramycin—Thrombocytopenia—Adefovir Dipivoxil—hepatitis B	0.00492	0.00492	CcSEcCtD
Tobramycin—Skin disorder—Adefovir Dipivoxil—hepatitis B	0.00488	0.00488	CcSEcCtD
Tobramycin—Ill-defined disorder—Telbivudine—hepatitis B	0.00481	0.00481	CcSEcCtD
Tobramycin—Anorexia—Adefovir Dipivoxil—hepatitis B	0.00479	0.00479	CcSEcCtD
Tobramycin—Malaise—Telbivudine—hepatitis B	0.00468	0.00468	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Adefovir Dipivoxil—hepatitis B	0.00458	0.00458	CcSEcCtD
Tobramycin—Cough—Telbivudine—hepatitis B	0.00452	0.00452	CcSEcCtD
Tobramycin—Dehydration—Lamivudine—hepatitis B	0.00451	0.00451	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Entecavir—hepatitis B	0.00445	0.00445	CcSEcCtD
Tobramycin—Chest pain—Telbivudine—hepatitis B	0.00441	0.00441	CcSEcCtD
Tobramycin—Myalgia—Telbivudine—hepatitis B	0.00441	0.00441	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Telbivudine—hepatitis B	0.00438	0.00438	CcSEcCtD
Tobramycin—Aspartate aminotransferase increased—Lamivudine—hepatitis B	0.00437	0.00437	CcSEcCtD
Tobramycin—Decreased appetite—Adefovir Dipivoxil—hepatitis B	0.00437	0.00437	CcSEcCtD
Tobramycin—Discomfort—Telbivudine—hepatitis B	0.00436	0.00436	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Adefovir Dipivoxil—hepatitis B	0.00434	0.00434	CcSEcCtD
Tobramycin—Muscular weakness—Lamivudine—hepatitis B	0.00428	0.00428	CcSEcCtD
Tobramycin—Gastrointestinal pain—Entecavir—hepatitis B	0.00421	0.00421	CcSEcCtD
Tobramycin—Nervous system disorder—Telbivudine—hepatitis B	0.00415	0.00415	CcSEcCtD
Tobramycin—Thrombocytopenia—Telbivudine—hepatitis B	0.00414	0.00414	CcSEcCtD
Tobramycin—Skin disorder—Telbivudine—hepatitis B	0.00411	0.00411	CcSEcCtD
Tobramycin—Gastrointestinal pain—Adefovir Dipivoxil—hepatitis B	0.00411	0.00411	CcSEcCtD
Tobramycin—Body temperature increased—Entecavir—hepatitis B	0.00407	0.00407	CcSEcCtD
Tobramycin—Abdominal pain—Entecavir—hepatitis B	0.00407	0.00407	CcSEcCtD
Tobramycin—Bronchitis—Lamivudine—hepatitis B	0.00403	0.00403	CcSEcCtD
Tobramycin—Abdominal pain—Adefovir Dipivoxil—hepatitis B	0.00397	0.00397	CcSEcCtD
Tobramycin—Body temperature increased—Adefovir Dipivoxil—hepatitis B	0.00397	0.00397	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Telbivudine—hepatitis B	0.00386	0.00386	CcSEcCtD
Tobramycin—Paraesthesia—Telbivudine—hepatitis B	0.0038	0.0038	CcSEcCtD
Tobramycin—Asthenia—Entecavir—hepatitis B	0.0037	0.0037	CcSEcCtD
Tobramycin—Renal failure—Lamivudine—hepatitis B	0.00368	0.00368	CcSEcCtD
Tobramycin—Neuropathy peripheral—Lamivudine—hepatitis B	0.00367	0.00367	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Telbivudine—hepatitis B	0.00365	0.00365	CcSEcCtD
Tobramycin—Stomatitis—Lamivudine—hepatitis B	0.00364	0.00364	CcSEcCtD
Tobramycin—Pain—Telbivudine—hepatitis B	0.00362	0.00362	CcSEcCtD
Tobramycin—Asthenia—Adefovir Dipivoxil—hepatitis B	0.00361	0.00361	CcSEcCtD
Tobramycin—Pruritus—Adefovir Dipivoxil—hepatitis B	0.00356	0.00356	CcSEcCtD
Tobramycin—Epistaxis—Lamivudine—hepatitis B	0.00353	0.00353	CcSEcCtD
Tobramycin—Diarrhoea—Entecavir—hepatitis B	0.00352	0.00352	CcSEcCtD
Tobramycin—Sinusitis—Lamivudine—hepatitis B	0.00351	0.00351	CcSEcCtD
Tobramycin—Agranulocytosis—Lamivudine—hepatitis B	0.00349	0.00349	CcSEcCtD
Tobramycin—Feeling abnormal—Telbivudine—hepatitis B	0.00349	0.00349	CcSEcCtD
Tobramycin—Gastrointestinal pain—Telbivudine—hepatitis B	0.00346	0.00346	CcSEcCtD
Tobramycin—Diarrhoea—Adefovir Dipivoxil—hepatitis B	0.00344	0.00344	CcSEcCtD
Tobramycin—Dizziness—Entecavir—hepatitis B	0.00341	0.00341	CcSEcCtD
Tobramycin—Rhinitis—Lamivudine—hepatitis B	0.00337	0.00337	CcSEcCtD
Tobramycin—Body temperature increased—Telbivudine—hepatitis B	0.00335	0.00335	CcSEcCtD
Tobramycin—Abdominal pain—Telbivudine—hepatitis B	0.00335	0.00335	CcSEcCtD
Tobramycin—Pharyngitis—Lamivudine—hepatitis B	0.00333	0.00333	CcSEcCtD
Tobramycin—Connective tissue disorder—Lamivudine—hepatitis B	0.0033	0.0033	CcSEcCtD
Tobramycin—Vomiting—Entecavir—hepatitis B	0.00328	0.00328	CcSEcCtD
Tobramycin—Rash—Entecavir—hepatitis B	0.00325	0.00325	CcSEcCtD
Tobramycin—Dermatitis—Entecavir—hepatitis B	0.00324	0.00324	CcSEcCtD
Tobramycin—Headache—Entecavir—hepatitis B	0.00323	0.00323	CcSEcCtD
Tobramycin—Vomiting—Adefovir Dipivoxil—hepatitis B	0.0032	0.0032	CcSEcCtD
Tobramycin—Rash—Adefovir Dipivoxil—hepatitis B	0.00317	0.00317	CcSEcCtD
Tobramycin—Dermatitis—Adefovir Dipivoxil—hepatitis B	0.00317	0.00317	CcSEcCtD
Tobramycin—Headache—Adefovir Dipivoxil—hepatitis B	0.00315	0.00315	CcSEcCtD
Tobramycin—Nausea—Entecavir—hepatitis B	0.00306	0.00306	CcSEcCtD
Tobramycin—Asthenia—Telbivudine—hepatitis B	0.00304	0.00304	CcSEcCtD
Tobramycin—Immune system disorder—Lamivudine—hepatitis B	0.00303	0.00303	CcSEcCtD
Tobramycin—Mediastinal disorder—Lamivudine—hepatitis B	0.00303	0.00303	CcSEcCtD
Tobramycin—Pruritus—Telbivudine—hepatitis B	0.00299	0.00299	CcSEcCtD
Tobramycin—Nausea—Adefovir Dipivoxil—hepatitis B	0.00299	0.00299	CcSEcCtD
Tobramycin—Erythema—Lamivudine—hepatitis B	0.00292	0.00292	CcSEcCtD
Tobramycin—Diarrhoea—Telbivudine—hepatitis B	0.0029	0.0029	CcSEcCtD
Tobramycin—Dysgeusia—Lamivudine—hepatitis B	0.00286	0.00286	CcSEcCtD
Tobramycin—Back pain—Lamivudine—hepatitis B	0.00283	0.00283	CcSEcCtD
Tobramycin—Dizziness—Telbivudine—hepatitis B	0.0028	0.0028	CcSEcCtD
Tobramycin—Ill-defined disorder—Lamivudine—hepatitis B	0.00271	0.00271	CcSEcCtD
Tobramycin—Anaemia—Lamivudine—hepatitis B	0.0027	0.0027	CcSEcCtD
Tobramycin—Vomiting—Telbivudine—hepatitis B	0.00269	0.00269	CcSEcCtD
Tobramycin—Angioedema—Lamivudine—hepatitis B	0.00267	0.00267	CcSEcCtD
Tobramycin—Rash—Telbivudine—hepatitis B	0.00267	0.00267	CcSEcCtD
Tobramycin—Dermatitis—Telbivudine—hepatitis B	0.00267	0.00267	CcSEcCtD
Tobramycin—Headache—Telbivudine—hepatitis B	0.00265	0.00265	CcSEcCtD
Tobramycin—Malaise—Lamivudine—hepatitis B	0.00264	0.00264	CcSEcCtD
Tobramycin—Vertigo—Lamivudine—hepatitis B	0.00263	0.00263	CcSEcCtD
Tobramycin—Leukopenia—Lamivudine—hepatitis B	0.00262	0.00262	CcSEcCtD
Tobramycin—Cough—Lamivudine—hepatitis B	0.00255	0.00255	CcSEcCtD
Tobramycin—Nausea—Telbivudine—hepatitis B	0.00251	0.00251	CcSEcCtD
Tobramycin—Chest pain—Lamivudine—hepatitis B	0.00249	0.00249	CcSEcCtD
Tobramycin—Myalgia—Lamivudine—hepatitis B	0.00249	0.00249	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—hepatitis B	0.00247	0.00247	CcSEcCtD
Tobramycin—Discomfort—Lamivudine—hepatitis B	0.00246	0.00246	CcSEcCtD
Tobramycin—Confusional state—Lamivudine—hepatitis B	0.0024	0.0024	CcSEcCtD
Tobramycin—Anaphylactic shock—Lamivudine—hepatitis B	0.00238	0.00238	CcSEcCtD
Tobramycin—Nervous system disorder—Lamivudine—hepatitis B	0.00234	0.00234	CcSEcCtD
Tobramycin—Thrombocytopenia—Lamivudine—hepatitis B	0.00233	0.00233	CcSEcCtD
Tobramycin—Skin disorder—Lamivudine—hepatitis B	0.00232	0.00232	CcSEcCtD
Tobramycin—Anorexia—Lamivudine—hepatitis B	0.00227	0.00227	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Lamivudine—hepatitis B	0.00217	0.00217	CcSEcCtD
Tobramycin—Paraesthesia—Lamivudine—hepatitis B	0.00214	0.00214	CcSEcCtD
Tobramycin—Dyspnoea—Lamivudine—hepatitis B	0.00213	0.00213	CcSEcCtD
Tobramycin—Decreased appetite—Lamivudine—hepatitis B	0.00207	0.00207	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Lamivudine—hepatitis B	0.00206	0.00206	CcSEcCtD
Tobramycin—Pain—Lamivudine—hepatitis B	0.00204	0.00204	CcSEcCtD
Tobramycin—Feeling abnormal—Lamivudine—hepatitis B	0.00197	0.00197	CcSEcCtD
Tobramycin—Gastrointestinal pain—Lamivudine—hepatitis B	0.00195	0.00195	CcSEcCtD
Tobramycin—Urticaria—Lamivudine—hepatitis B	0.00189	0.00189	CcSEcCtD
Tobramycin—Abdominal pain—Lamivudine—hepatitis B	0.00189	0.00189	CcSEcCtD
Tobramycin—Body temperature increased—Lamivudine—hepatitis B	0.00189	0.00189	CcSEcCtD
Tobramycin—Hypersensitivity—Lamivudine—hepatitis B	0.00176	0.00176	CcSEcCtD
Tobramycin—Asthenia—Lamivudine—hepatitis B	0.00171	0.00171	CcSEcCtD
Tobramycin—Pruritus—Lamivudine—hepatitis B	0.00169	0.00169	CcSEcCtD
Tobramycin—Diarrhoea—Lamivudine—hepatitis B	0.00163	0.00163	CcSEcCtD
Tobramycin—Dizziness—Lamivudine—hepatitis B	0.00158	0.00158	CcSEcCtD
Tobramycin—Vomiting—Lamivudine—hepatitis B	0.00152	0.00152	CcSEcCtD
Tobramycin—Rash—Lamivudine—hepatitis B	0.0015	0.0015	CcSEcCtD
Tobramycin—Dermatitis—Lamivudine—hepatitis B	0.0015	0.0015	CcSEcCtD
Tobramycin—Headache—Lamivudine—hepatitis B	0.00149	0.00149	CcSEcCtD
Tobramycin—Nausea—Lamivudine—hepatitis B	0.00142	0.00142	CcSEcCtD
